Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 2/20 | 0.32 |
| ▸ | GBA1 | P04062 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190589 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2GLB1GUSBGBA1 | |
| SCHEMBL2190593 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2GLB1GUSBGBA1 | |
| SCHEMBL11333949 | 0.82 | GLB1 (0.36) | GLB1GUSBGBA1 | |
| SCHEMBL11333962 | 0.82 | GLB1 (0.36) | GLB1GUSBGBA1 | |
| SCHEMBL11333955 | 0.82 | GLB1 (0.36) | GLB1GUSBGBA1 | |
| SCHEMBL23475172 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2GLB1GUSBGBA1 | |
| SCHEMBL13037926 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2GLB1GUSBGBA1 | |
| SCHEMBL14120089 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2GLB1GUSBGBA1 | |
| SCHEMBL12560951 | 0.77 | RORC (0.37) | SMN1; SMN2 | |
| SCHEMBL25033588 | 0.77 | RORC (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351738-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL | Sumitomo Chemical Company, Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | TEAD4, TEAD3, TEAD2 | SMN1; SMN2 4312/4885GLB1 1890/4885GUSB 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.